Autobio Diagnostics (603658) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 was RMB 995.93 million, down 8.56% year-over-year.

• Net profit attributable to shareholders was RMB 269.88 million, a 16.76% decrease year-over-year.

• Cash flow from operating activities dropped 49.35% to RMB 166.34 million compared to the same period last year.

Financial highlights

• Basic and diluted EPS were RMB 0.47, down from RMB 0.56 in Q1 2024.

• Gross margin and operating profit both declined, with total assets at RMB 11.97 billion, up slightly from year-end.

• Net assets attributable to shareholders increased to RMB 8.88 billion.

• Non-recurring profit items contributed RMB 12.99 million, mainly from government subsidies and investment returns.

Key financial ratios and metrics

• Weighted average ROE was 3.09%, down 0.65 percentage points year-over-year.

• Operating cash flow margin declined sharply due to lower sales receipts.